Open Access in mAbs
mAbs offers a highly competitive open access fee for authors who wish for free access to and distribution of published articles. Authors retain copyright of their work by utilizing a Creative Commons attribution license. Open Access papers will be submitted to PubMed Central immediately upon final publication of each issue.
The cost to make an original research paper OA is $750.00 USD.
For all other types of papers, the OA fee is $500.00 USD.
Special Discounted Subscription for Antibody Society Members
is an official therapeutics journal of The Antibody Society and offers a discounted subscription to Society members for $49. If you're a member and you'd like to take advantage of this offer, please contact Kyle Funk
'Like' mAbs on Facebook!
'Like' mAbs on Facebook to find out about newly added PDFs to forthcoming issues.
About the Journal
mAbs is an international peer-reviewed journal focused exclusively on antibodies.
Our mission is to provide a forum for communication on all topics relevant to antibody research and development, with a focus on therapeutics. In the last decade, there has been a rapid increase in antibody research and development performed by academia, government and industry located world wide. Novel antibody therapeutics are entering clinical study by commercial sponsors at an average rate of 50 per year that is predicted to continue well into the future. Over 30 mAb therapeutics have been approved and global sales of these products are approximately $40 billion. Our broad scope ensures that the journal's articles are of interest to scientists, clinical researchers, and physicians, as well as the wider mAb community including readers concerned with technology transfer, legal issues, investment, regulatory requirements and strategic planning.